KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes...<< Prices as on May 16, 2025 - 3:59PM >>  ABB India 5828.95  [ 1.65% ]  ACC 1922.7  [ 2.12% ]  Ambuja Cements 563.3  [ 2.96% ]  Asian Paints Ltd. 2353.15  [ 0.98% ]  Axis Bank Ltd. 1208.3  [ 0.06% ]  Bajaj Auto 8487.15  [ 1.91% ]  Bank of Baroda 236.85  [ 1.02% ]  Bharti Airtel 1814.35  [ -2.81% ]  Bharat Heavy Ele 250.35  [ 1.89% ]  Bharat Petroleum 320.15  [ 1.01% ]  Britannia Ind. 5503.7  [ 0.73% ]  Cipla 1499.7  [ -0.17% ]  Coal India 404.7  [ 0.06% ]  Colgate Palm. 2690.25  [ 1.26% ]  Dabur India 476.4  [ 1.61% ]  DLF Ltd. 715.95  [ 0.92% ]  Dr. Reddy's Labs 1230.5  [ -0.35% ]  GAIL (India) 186.35  [ 0.73% ]  Grasim Inds. 2800  [ -0.88% ]  HCL Technologies 1659.75  [ -2.14% ]  HDFC Bank 1933.65  [ -0.01% ]  Hero MotoCorp 4339.8  [ 0.42% ]  Hindustan Unilever L 2381  [ 1.10% ]  Hindalco Indus. 657.45  [ -0.60% ]  ICICI Bank 1453.65  [ 0.19% ]  Indian Hotels Co 766.05  [ 0.26% ]  IndusInd Bank 782.3  [ 0.26% ]  Infosys L 1589.75  [ -1.46% ]  ITC Ltd. 435.6  [ 0.73% ]  Jindal St & Pwr 980  [ 1.29% ]  Kotak Mahindra Bank 2107.9  [ 0.08% ]  L&T 3605.7  [ -0.34% ]  Lupin Ltd. 2065  [ -0.31% ]  Mahi. & Mahi 3134  [ -0.31% ]  Maruti Suzuki India 12964.3  [ 0.13% ]  MTNL 44.8  [ 5.02% ]  Nestle India 2410.55  [ 0.52% ]  NIIT Ltd. 139.35  [ -0.04% ]  NMDC Ltd. 70.21  [ 0.23% ]  NTPC 343.15  [ 0.35% ]  ONGC 247.35  [ -0.06% ]  Punj. NationlBak 98.9  [ 0.61% ]  Power Grid Corpo 300.3  [ 0.23% ]  Reliance Inds. 1456.6  [ 0.19% ]  SBI 791.85  [ -1.96% ]  Vedanta 441  [ -0.65% ]  Shipping Corpn. 188.85  [ 9.26% ]  Sun Pharma. 1733  [ -0.38% ]  Tata Chemicals 859.75  [ 0.92% ]  Tata Consumer Produc 1162.65  [ 1.40% ]  Tata Motors 730.7  [ 0.36% ]  Tata Steel 157.45  [ 0.06% ]  Tata Power Co. 405.7  [ 1.93% ]  Tata Consultancy 3562.95  [ -0.50% ]  Tech Mahindra 1615.15  [ -0.79% ]  UltraTech Cement 11890  [ 0.01% ]  United Spirits 1535.6  [ -0.21% ]  Wipro 254.5  [ -0.78% ]  Zee Entertainment En 129.55  [ 2.05% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

MANKIND PHARMA LTD.

16 May 2025 | 03:56

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE634S01028 BSE Code / NSE Code 543904 / MANKIND Book Value (Rs.) 256.10 Face Value 1.00
Bookclosure 52Week High 3055 EPS 46.36 P/E 55.49
Market Cap. 106144.08 Cr. 52Week Low 1901 P/BV / Div Yield (%) 10.05 / 0.00 Market Lot 1.00
Security Type Other

History of Company

The company history sections lists out major chronological events that happened to the company.
Our Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of our Company to a public limited company and as approved by our Shareholders pursuant to a special resolution dated July 14, 2005 the name of our Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.

Major events and milestones:

2004 
Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar'
tablets amongst others

2005 
-Set up our first manufacturing facility at Paonta Sahib, Himachal Pradesh
-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others

2007 
-Entered the consumer healthcare segment with the launch of `Manforce' brand
-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised ? 720 million from Monet Limited

2009 
Set up our manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh

2010 
Launched `Preganews' brand in the consumer healthcare segment

2012 
Setup our first R&D centre at IMT Manesar, Haryana

2014 
-Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)
-Set up our manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh

2015 
-Incorporated our Subsidiary, Lifestar Pharma LLC in the US
-Incorporated our Subsidiary, Mankind Pharma Pte. Limited in Singapore

2017 
Set up our manufacturing facility in Sikkim

2018 
Our manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time

2019 
Entered the female infertility segment with the launch of `Dydroboon' tablets

2020 
-Incorporated our Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal
-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets
-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets

2021 
-Incorporated our Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE
-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets
-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets

2022 
-Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited
-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others
-Entered into oncology segment with the launch of `Pacliall' injection amongst others
-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories
-Our Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited.

2023 -Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence. -Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API. -Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.

2024 -Mankind Pharma Completes Landmark Acquisition of BSV. -Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab. -Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups. -Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain).